Heart Failure, Diabetes & SGLT2i: Time to change practice?
CME accredited symposium to be held at Heart fail;ure 2019 in Athens, GreeceAgenda - May 25, 2019 - Heart Failure 2019, Athens, Greece
If you are attending Heart Failure 2019 in Athens, Greece, you are cordially invited to attend this CME accredited Symposium
Saturday, May 25, 2019: 13:30 – 14:30 hrs
Educational objectives of this symposium include to:
- To explore mechanisms and common pathways underlying the development of cardiovascular disease and heart failure and the particular risk of patients with diabetes
- To discuss the role of anti-diabetic therapy, in particular the use of SGLT2 inhibitors, in a risk-based intervention strategy that targets glucose control and cardiovascular risk factors
- To discuss current and future strategies for practical management of heart failure and interventions to prevent cardiovascular events
- Introduction: The essentials for Diabetes and heart failure, Martin Cowie, MD, London, United Kingdom
- Why could SGLT2i benefit in patients with HF and T2DM?, Subodh Verma, MD, Toronto, Canada
- Real world practices and outcomes in the management of patients with T2DM and HF, Carolyn Lam, MD Singapore//
- The future of SGLT2i in HF: Managing patients without T2DM?, Adriaan Voors, MD, , Groningen, The Netherlands
- Panel discussion
This programme is accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of external CME credit(s). Each participant should claim only those hours of credit that have actually been spent in the educational activity. The Accreditation Council for Continuing Medical Education (ACCME®) and EBAC have recognized each other’s accreditation systems as substantially equivalent.
This symposium is funded by an unrestricted educational grant received from Boehringer Ingelheim/Lilly